Presentation
Aims
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 21st AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.
Addressed to
Scientific Program
Thursday, September 11th
10:30 | Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat |
SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
Chairpersons: Pierfranco Conte, Aleix Prat
11.00 | Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas Alberto Zambelli |
11.20 | The immune system and breast cancer: TNBC and beyond Maria Vittoria Dieci |
11.40 | DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer Mafalda Oliveira |
12.00 | Tackling the biological diversity in HER2-positive breast cancer: clinical implications Aleix Prat |
12.20 | Discussion |
12.50 | Lunch |
SESSION II – GENETIC PREDISPOSITION TO BREAST CANCER
Chairpersons: Bettina Borisch, Fedro Peccatori
14.00 | Genetic testing beyond BRCA Teresa Ramon y Cajal |
14.20 | Challenges in locoregional treatments:
|
15.00 | Systemic treatment options in patients with genetic predisposition with Early and Advanced disease Sandra Swan |
15.30 | Discussion |
16.00 | Coffee break |
SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY
Chairpersons: Giuseppe Curigliano, Sibylle Loibl
16.20 | Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ Sibylle Loibl |
16.40 | Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC Hope Rugo |
17.00 | Neoadjuvant Treatment in HR+HER2-BC: why, when, which one Valentina Guarneri |
17.20 | Response-guided radiotherapy after neoadjuvant treatments Angel Montero Luis |
17.40 | Discussion |
18.00 | Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2025 |
18.15 | Lecture of the Awardee |
18.45 | Adjourn |
Friday, September 12th
SESSION IV – EARLY BREAST CANCER
Chairpersons: Lucia del Mastro, Michelino De Laurentiis
9.00 | Enhancing efficacy of hormonal therapy in early breast cancer Stephen Johnston |
9.20 | Adjuvant treatments for rare histologies: how to manage uncertainty Valentina Guarneri |
9.40 | Life style intervention after breast cancer Claudio Vernieri |
10.00 | Discussion |
10.30 | Coffee break |
11.00 | Clinical Multidisciplinary Shooting Session 1 – Early Breast Cancer Panelist: Lucia Del Mastro, Michelino De Laurentiis, Hesham Ahmed Gaballah Elghazaly, Stephen Johnston, Eleftherios Mamounas, Philip Poortmans, Hope Rugo, Sandra Swain |
12.30 | Lunch |
SESSION V – METASTATIC BREAST CANCER: STATE OF ART AND TRIALS LIKELY TO IMPACT IN THE FUTURE
Chairpersons: Alessandra Gennari, Fabio Puglisi
13.30 | HR+ disease Laura Biganzoli |
14.00 | HER2+ disease Giuseppe Curigliano |
14.30 | Triple negative disease Giampaolo Bianchini |
15.00 | Discussion |
15.20 | Clinical Multidisciplinary Shooting Session 2 – Advanced Breast Cancer Panelist: Hesham Ahmed Gaballah Elghazaly , Alessandra Gennari, Jacek Jassem, Stephen Johnston, Eleftherios Mamounas, Fabio Puglisi, Sandra Swain, Hope Rugo |
16.40 | Take home messages and adjourn Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans |
CME
Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-419161): 12 CME points.
Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.
To obtain CME credits, participants must meet the following requirements:
- Their declared profession/specialization must correspond to those accredited for CME;
- They must attend at least 90% of the course;
- They must complete the online meeting evaluation form;
- They must pass the learning assesment test with at least 75% correct answers. Only one attempt is allowed.
The learning assessment test and meeting evaluation form must be submitted within three days of the event.
Meeting Venue
Via San Francesco, 90 – Padua
The Center is located in the ZTL area. We recommend the Interparking Italia – Via Trieste 50.
Award & Fellowships
Faculty
Directors
Scientific Committee
Bettina Borisch
Institute of Global Health
Geneve (CH)
Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
Padova (IT)
Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)
Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)
Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)
Sibylle Loibl
German Breast Group
University of Frankfurt (DE)
Eleftherios Mamounas
Comprehensive Breast Program
MD Anderson Cancer Center Orlando
Orlando (US)
Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (IT)
Sandra M. Swain
Professor of Medicine, Associate Dean Research Development
Georgetown University Medical Center
Washington (US)
Speakers
Giampaolo Bianchini
Milano (IT)
Laura Biganzoli
Prato (IT)
Giuseppe Curigliano
University of Milano (IT)
Michelino De Laurentiis
Napoli (IT)
Lucia Del Mastro
Genova (IT)
Alesssandra Gennari
Novara (IT)
Angel Montero Luis
Madrid (ES)
Mafalda Oliveira
Barcellona (ES)
Fabio Puglisi
Aviano (IT)
Hope Rugo
San Francisco (US)
Teresa Ramon j Cajal
Barcelona (ES)
Claudio Vernieri
Milano (IT)
Alberto Zambelli
Bergamo (IT)